After a dismal 2022, a number of SPAC mergers have outperformed this year alongside a strong rebound in IPO returns and the broader stock market. While most de-SPACs continue to trade below the $10 transaction price, investors may be finding hidden gems among...read more
Seven IPOs and five SPACs entered the public markets this week led by top performer Vital Farms (VITL), which popped 60% in its public debut. Vital Farms (VITL), the largest US producer of pasture-raised eggs, upsized and priced above...read more
NewHold Investment, a blank check company formed by NewHold Enterprises targeting an industrial technology business, raised $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable...read more
Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015.
Some major news hit the IPO...read more
28 SPAC mergers that have outperformed in 2023
After a dismal 2022, a number of SPAC mergers have outperformed this year alongside a strong rebound in IPO returns and the broader stock market. While most de-SPACs continue to trade below the $10 transaction price, investors may be finding hidden gems among...read more
US IPO Weekly Recap: Vital Farms pops 60% in a 7 IPO week
Seven IPOs and five SPACs entered the public markets this week led by top performer Vital Farms (VITL), which popped 60% in its public debut. Vital Farms (VITL), the largest US producer of pasture-raised eggs, upsized and priced above...read more
Industrial technology SPAC NewHold Investment prices $150 million IPO at $10
NewHold Investment, a blank check company formed by NewHold Enterprises targeting an industrial technology business, raised $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable...read more
US IPO Weekly Recap: Preclinical biotech Nkarta pops 166% in a 5 IPO week
Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015. Some major news hit the IPO...read more